◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › PYPD

PolyPid Ltd. (PYPD) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

PolyPid Ltd. (PYPD) operates in the Biotechnology industry and is headquartered in Petah Tikva, Israel with about 69 employees. Its market capitalization is roughly $104 million. In the fiscal year ended 2025-12-31, PYPD reported $0M in revenue and ($34M) in net income.

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.

Interactive charts & full statements →

PYPD Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($33M)($28M)($23M)($39M)
Net Income($34M)($29M)($24M)($40M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PYPD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($8M)($8M)($8M)($9M)($8M)
Net Income($8M)($8M)($8M)($10M)($8M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PYPD Free Cash Flow History

PYPD Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$22M$25M$15M$26M
Total Liabilities$11M$18M$18M$20M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PYPD viewer.

Other Companies in Biotechnology

← PXSAll stocksPYPL →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.